Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut J Ehrlich

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Vaccine|November 15, 2003
Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicityHartmut J Ehrlich, Borislava G Pavlova, Sandor Fritsch, et al.
The Journal of Infectious Diseases|May 20, 2011
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humansKlaus K Orlinger, Yvonne Hofmeister, Richard Fritz, et al.
Virology Journal|April 18, 2014
Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID miceChristine Hohenadl, Walter Wodal, Astrid Kerschbaum, et al.
Transfusion|October 11, 2011
Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenzaThomas R Kreil, John K Mc Vey, Laura Shau-Ping Lei, et al.
Vaccine|May 4, 2010
Comparison of immunogenicity and safety between two paediatric TBE vaccinesEva Maria Pöllabauer, Borislava G Pavlova, Alexandra Löw-Baselli, et al.
Plos One|February 2, 2011
Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunityAnnett Hessel, Michael Schwendinger, Georg W Holzer, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2022
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extensionSeverine Vermeire, Bruce E Sands, Herbert Tilg, et al.
Vaccine|August 1, 2012
A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memoryAlexandra Loew-Baselli, Borislava G Pavlova, Sandor Fritsch, et al.
Vaccine|August 14, 2012
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose primingMaikel V W van der Velden, Gerald Aichinger, Eva Maria Pöllabauer, et al.
Vaccine|April 6, 2012
Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccineHartmut J Ehrlich, Markus Müller, Herwig Kollaritsch, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Vaccine|November 15, 2003
Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicityHartmut J Ehrlich, Borislava G Pavlova, Sandor Fritsch, et al.
The Journal of Infectious Diseases|May 20, 2011
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humansKlaus K Orlinger, Yvonne Hofmeister, Richard Fritz, et al.
Virology Journal|April 18, 2014
Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID miceChristine Hohenadl, Walter Wodal, Astrid Kerschbaum, et al.
Transfusion|October 11, 2011
Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenzaThomas R Kreil, John K Mc Vey, Laura Shau-Ping Lei, et al.
Vaccine|May 4, 2010
Comparison of immunogenicity and safety between two paediatric TBE vaccinesEva Maria Pöllabauer, Borislava G Pavlova, Alexandra Löw-Baselli, et al.
Plos One|February 2, 2011
Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunityAnnett Hessel, Michael Schwendinger, Georg W Holzer, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2022
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extensionSeverine Vermeire, Bruce E Sands, Herbert Tilg, et al.
Vaccine|August 1, 2012
A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memoryAlexandra Loew-Baselli, Borislava G Pavlova, Sandor Fritsch, et al.
Vaccine|August 14, 2012
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose primingMaikel V W van der Velden, Gerald Aichinger, Eva Maria Pöllabauer, et al.
Vaccine|April 6, 2012
Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccineHartmut J Ehrlich, Markus Müller, Herwig Kollaritsch, et al.
Pageof 5